JP4283675B2 - 偏極129xeを用いる慢性心不全のような心肺障害を評価するための方法を含む、生理学的状態、および/または器官もしくは系の機能のインビボ評価のための方法 - Google Patents
偏極129xeを用いる慢性心不全のような心肺障害を評価するための方法を含む、生理学的状態、および/または器官もしくは系の機能のインビボ評価のための方法 Download PDFInfo
- Publication number
- JP4283675B2 JP4283675B2 JP2003529182A JP2003529182A JP4283675B2 JP 4283675 B2 JP4283675 B2 JP 4283675B2 JP 2003529182 A JP2003529182 A JP 2003529182A JP 2003529182 A JP2003529182 A JP 2003529182A JP 4283675 B2 JP4283675 B2 JP 4283675B2
- Authority
- JP
- Japan
- Prior art keywords
- polarized
- barrier
- signal
- gas
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 21
- 210000000056 organ Anatomy 0.000 title claims description 9
- 206010007558 Cardiac failure chronic Diseases 0.000 title claims description 4
- 238000000034 method Methods 0.000 title description 58
- 238000001727 in vivo Methods 0.000 title description 19
- 230000002612 cardiopulmonary effect Effects 0.000 title description 4
- 239000007789 gas Substances 0.000 claims description 129
- 210000004369 blood Anatomy 0.000 claims description 79
- 239000008280 blood Substances 0.000 claims description 79
- 210000004379 membrane Anatomy 0.000 claims description 57
- 210000001519 tissue Anatomy 0.000 claims description 55
- 239000012528 membrane Substances 0.000 claims description 54
- 230000004888 barrier function Effects 0.000 claims description 52
- 210000004072 lung Anatomy 0.000 claims description 51
- 230000010287 polarization Effects 0.000 claims description 46
- 210000004556 brain Anatomy 0.000 claims description 45
- 230000010412 perfusion Effects 0.000 claims description 42
- 239000000126 substance Substances 0.000 claims description 40
- 230000005284 excitation Effects 0.000 claims description 33
- 230000008499 blood brain barrier function Effects 0.000 claims description 16
- 229910052756 noble gas Inorganic materials 0.000 claims description 16
- 210000001218 blood-brain barrier Anatomy 0.000 claims description 14
- 238000009423 ventilation Methods 0.000 claims description 14
- 210000005013 brain tissue Anatomy 0.000 claims description 13
- 210000001601 blood-air barrier Anatomy 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 8
- 210000004884 grey matter Anatomy 0.000 claims description 8
- 239000001301 oxygen Substances 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 210000005166 vasculature Anatomy 0.000 claims description 8
- 238000003860 storage Methods 0.000 claims description 7
- 210000004885 white matter Anatomy 0.000 claims description 7
- 238000011156 evaluation Methods 0.000 claims description 5
- 230000000968 intestinal effect Effects 0.000 claims description 4
- 210000005152 placental membrane Anatomy 0.000 claims description 4
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 3
- 230000035790 physiological processes and functions Effects 0.000 claims description 3
- 239000011800 void material Substances 0.000 claims description 3
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 claims description 2
- 208000033626 Renal failure acute Diseases 0.000 claims description 2
- 201000011040 acute kidney failure Diseases 0.000 claims description 2
- 208000012998 acute renal failure Diseases 0.000 claims description 2
- 210000003484 anatomy Anatomy 0.000 claims description 2
- 208000020832 chronic kidney disease Diseases 0.000 claims description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims description 2
- 238000009826 distribution Methods 0.000 claims description 2
- 230000009977 dual effect Effects 0.000 claims description 2
- 210000005086 glomerual capillary Anatomy 0.000 claims description 2
- 230000024924 glomerular filtration Effects 0.000 claims description 2
- 230000001744 histochemical effect Effects 0.000 claims description 2
- 230000001771 impaired effect Effects 0.000 claims description 2
- 208000017169 kidney disease Diseases 0.000 claims description 2
- 210000002429 large intestine Anatomy 0.000 claims description 2
- 230000000284 resting effect Effects 0.000 claims description 2
- 206010037423 Pulmonary oedema Diseases 0.000 claims 1
- 208000005333 pulmonary edema Diseases 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 230000002123 temporal effect Effects 0.000 claims 1
- 230000006870 function Effects 0.000 description 39
- 238000005481 NMR spectroscopy Methods 0.000 description 36
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 35
- 229910052724 xenon Inorganic materials 0.000 description 29
- 230000002685 pulmonary effect Effects 0.000 description 22
- 238000001228 spectrum Methods 0.000 description 22
- 238000003384 imaging method Methods 0.000 description 19
- 238000002595 magnetic resonance imaging Methods 0.000 description 18
- 230000017531 blood circulation Effects 0.000 description 17
- 230000006399 behavior Effects 0.000 description 15
- 210000002216 heart Anatomy 0.000 description 15
- 239000003814 drug Substances 0.000 description 14
- 210000001736 capillary Anatomy 0.000 description 13
- 230000004044 response Effects 0.000 description 13
- 238000004590 computer program Methods 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 238000010586 diagram Methods 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 238000012544 monitoring process Methods 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 9
- 230000035479 physiological effects, processes and functions Effects 0.000 description 9
- 238000012545 processing Methods 0.000 description 9
- 230000003595 spectral effect Effects 0.000 description 9
- 229910052783 alkali metal Inorganic materials 0.000 description 8
- 150000001340 alkali metals Chemical class 0.000 description 8
- 230000003788 cerebral perfusion Effects 0.000 description 8
- 210000003743 erythrocyte Anatomy 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 238000009792 diffusion process Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000004611 spectroscopical analysis Methods 0.000 description 7
- 229940124597 therapeutic agent Drugs 0.000 description 7
- 201000009906 Meningitis Diseases 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- 150000002835 noble gases Chemical class 0.000 description 6
- 108091006146 Channels Proteins 0.000 description 5
- 206010021143 Hypoxia Diseases 0.000 description 5
- 208000006011 Stroke Diseases 0.000 description 5
- 210000000709 aorta Anatomy 0.000 description 5
- 230000005415 magnetization Effects 0.000 description 5
- 238000002798 spectrophotometry method Methods 0.000 description 5
- 230000000747 cardiac effect Effects 0.000 description 4
- 230000003727 cerebral blood flow Effects 0.000 description 4
- 230000002490 cerebral effect Effects 0.000 description 4
- 239000000306 component Substances 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000005240 left ventricle Anatomy 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 239000000700 radioactive tracer Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 206010061818 Disease progression Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000005750 disease progression Effects 0.000 description 3
- 238000004535 dynamic nuclear magnetic resonance Methods 0.000 description 3
- 210000001308 heart ventricle Anatomy 0.000 description 3
- 230000007954 hypoxia Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 3
- 238000005086 pumping Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 208000016192 Demyelinating disease Diseases 0.000 description 2
- 206010012305 Demyelination Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 2
- 210000002376 aorta thoracic Anatomy 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 210000003989 endothelium vascular Anatomy 0.000 description 2
- 230000005283 ground state Effects 0.000 description 2
- 230000002102 hyperpolarization Effects 0.000 description 2
- 230000001146 hypoxic effect Effects 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000003169 placental effect Effects 0.000 description 2
- 230000000541 pulsatile effect Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 230000000304 vasodilatating effect Effects 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- 238000004480 129Xe NMR spectroscopy Methods 0.000 description 1
- 208000007788 Acute Liver Failure Diseases 0.000 description 1
- 206010000804 Acute hepatic failure Diseases 0.000 description 1
- 206010001889 Alveolitis Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010021036 Hyponatraemia Diseases 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000836 acute liver failure Toxicity 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 238000011861 anti-inflammatory therapy Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000036978 cell physiology Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007435 diagnostic evaluation Methods 0.000 description 1
- 210000001038 distal kidney tubule Anatomy 0.000 description 1
- 238000012362 drug development process Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 230000004578 fetal growth Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- SWQJXJOGLNCZEY-BJUDXGSMSA-N helium-3 atom Chemical compound [3He] SWQJXJOGLNCZEY-BJUDXGSMSA-N 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000001286 intracranial vasospasm Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000005246 left atrium Anatomy 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 210000003492 pulmonary vein Anatomy 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000013125 spirometry Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- FHNFHKCVQCLJFQ-YPZZEJLDSA-N xenon-129 atom Chemical compound [129Xe] FHNFHKCVQCLJFQ-YPZZEJLDSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/48—NMR imaging systems
- G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
- G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
- G01R33/5601—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/48—NMR imaging systems
- G01R33/483—NMR imaging systems with selection of signals or spectra from particular regions of the volume, e.g. in vivo spectroscopy
- G01R33/485—NMR imaging systems with selection of signals or spectra from particular regions of the volume, e.g. in vivo spectroscopy based on chemical shift information [CSI] or spectroscopic imaging, e.g. to acquire the spatial distributions of metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/48—NMR imaging systems
- G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
- G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
- G01R33/563—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution of moving material, e.g. flow contrast angiography
- G01R33/56308—Characterization of motion or flow; Dynamic imaging
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- High Energy & Nuclear Physics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Radiology & Medical Imaging (AREA)
- General Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Signal Processing (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Description
特定の実施態様において、本発明の方法によって、インビボで選択された部位または環境において偏極129Xeの挙動に対応する動的NMR分光光学的シグナルデータが獲得される。このシグナルデータは、以下を評価するために用いることができる:(a)膜、臓器、組織、または他の生理学的構造もしくは環境の生理学(組織容積または厚み/幅);(b)膜、身体系、またはその部分の動作状態または機能;(c)脳灌流;および/または(c)診断された障害、疾患、または状態を処置するために用いた治療処置の有効性。したがって、本発明は、障害または疾患をスクリーニングおよび/または診断するための方法、ならびに/あるいは障害または疾患を処置するために被験体に投与された治療剤の有効性をモニタリングするための方法を提供する。
本発明は、本発明の実施態様が示される、添付の図面を参照して、本明細書中の以降においてより詳細に記載される。しかし、本発明は、多くの異なる形態で具現化され得、したがって、本明細書に記載の実施態様に対して限定されると解釈されるべきではない。全体を通して、同様の数は同様の要素を指す。図面において、層、領域または特徴を明確に強調することができる。図面における破線は、必要に応じた特徴または操作に相当する。
Claims (29)
- 溶存相の偏極129Xeを用いて、被験体における生理学的障壁の厚み又は幅を評価するためのシステムであって、上記生理学的障壁が第一の環境と第二の環境とを隔てており、偏極129Xeが第一の環境、上記障壁及び第二の環境へと順次移動し、偏極129Xeが第一及び第二の環境並びに上記障壁において異なるNMRシグナル化学シフト周波数を示し、当該システムが、
上記障壁及び第二の環境における129Xeの偏極を破壊する手段と、
偏極129Xeが上記障壁を横切って上記第二の環境に入るときの上記偏極129Xeの代表的な挙動の上記NMR分光光学的シグナルの値の経時的な少なくとも1つの第一の動的データセットを生成するため第二の化学シフトにおいて上記被験体における偏極ガスのNMR分光光学的シグナルを獲得する手段と、
上記獲得する手段によって得られるデータに基づいて、上記偏極ガスの上記偏極ガス通過時間を評価する手段であって、上記ガス通過時間が、上記偏極ガスが上記障壁を横切って移動し、次いで上記第二の環境に入るのに要する時間に対応している手段と、
上記評価する手段によって得られたデータに基づいて上記障壁の厚み又は幅を決定する手段と
を含むシステム。 - 前記生理学的な障壁が肺胞毛細管膜であり、当該システムが、さらに、休止期及びストレス期におけるガス通過時間を比較して、肺胞毛細管膜の機能を評価する手段をさらに含む請求項1に記載のシステム。
- 前記評価する手段を用いて、1ミクロン〜100ミクロンの範囲内の厚み又は幅を有する障壁を測定する、請求項1に記載のシステム。
- 前記第一の環境が肺の空隙又は肺の脈管構造組織であり、前記障壁が肺胞毛細管膜を含み、前記第二の環境が肺の血液である、請求項1に記載のシステム。
- 前記生理学的な障壁が、糸球体毛細血管膜、腸膜、胎盤膜、及び血液脳関門のうちの1つである、請求項1に記載のシステム。
- 前記肺胞毛細管膜の機能を評価する手段をさらに含む請求項1に記載のシステム。
- 二重同調した129Xe及び1H RF励起コイルを用いて目的の解剖学的構造のMR画像を作製する手段をさらに含む請求項1に記載のシステム。
- 偏極希ガス129Xeの換気分布MRIを獲得する手段をさらに含む請求項1に記載のシステム。
- 前記評価する手段に少なくとも一部は基づいて、慢性心不全の有無を決定する手段をさらに含む請求項2に記載のシステム。
- さらに、
動的データにフィットするシグナル強度対時間の曲線を作成する手段と、
上記曲線の時定数を特定する手段と、及び
上記時定数に対応する曲線に沿う時点で上記シグナル強度の振幅を評価する手段と
を含む請求項1に記載のシステム。 - NMR分光光学的シグナル値の少なくとも1つの動的データセットを経時的に作成するため前記第一の環境における前記第一の化学シフトで前記被験体における偏極ガスの第二のNMR分光光学的シグナルを獲得する手段と、
上記第一の環境についての上記動的データにフィットするシグナル強度対時間曲線を作成する手段と
をさらに含む請求項1に記載のシステム。 - 肺線維症又は肺水腫を評価する手段をさらに含む請求項2に記載のシステム。
- 糸球体濾過速度、急性及び慢性の腎不全、ネフローゼ症候群、糸球体腎炎、及び他の腎臓疾患の少なくとも1つを評価する手段をさらに含む請求項1に記載のシステム。
- 大腸及び小腸の壁の厚み、完全性又は機能を評価する手段をさらに含む請求項1に記載のシステム。
- 胎盤膜機能を定量的に評価する手段をさらに含む請求項1に記載のシステム。
- 血液脳関門を評価する手段をさらに含む請求項1に記載のシステム。
- 呼吸器疾患について患者を評価する手段をさらに含む請求項1に記載のシステム。
- 前記生理学的な障壁が前記被験体の身体内の膜又は裏打ちである、請求項1に記載のシステム。
- 前記生理学的な障壁が腸壁である、請求項1に記載のシステム。
- 前記生理学的な障壁が血液脳関門である、請求項1に記載のシステム。
- 前記獲得する手段及び評価する手段に少なくとも一部は基づいて、臓器又は脳の灌流を評価する手段をさらに含む請求項1に記載のシステム。
- 上記第一の化学シフト周波数においてNMR分光光学的シグナル値の第二の動的データセットを経時的に作成するため前記第一の化学シフトにおいて前記被験体における前記偏極ガスのNMR分光光学的シグナルを獲得する手段をさらに含む、前記第一の動的データが、ミリ秒の分解能で経時的に組織中の偏極129Xeのシグナルの勾配を規定する手段と、上記動的データの各々に対してフィットする曲線を作成する手段とをさらに含む、請求項1に記載のシステム。
- 前記第二の動的データセットが、組織中の偏極129Xeの挙動に対応し、上記関連する曲線のピーク振幅が組織容積に相当する請求項22に記載のシステム。
- 前記動的データに対してフィットするシグナル強度のラインを経時的に作成する手段をさらに含んでおり、上記ラインが関連する時定数、勾配とつながる直線部分、及び経時的なシグナル強度振幅を有し、前記評価する手段が、上記ラインに関連するパラメーターであって、時定数、この時定数に対応する時点のシグナル振幅、ピークシグナル振幅、及び上記曲線の上記直線部分につながる上記勾配のうちの少なくとも1つを含むパラメーターを考慮する、請求項1に記載のシステム。
- 血液及び脳組織において異なるNMR化学シフトシグナル周波数を示す偏極129Xeを用いて、被験体における血液脳関門を評価するためのシステムであって、当該システムが、
脳組織における偏極129Xeの偏極を破壊する手段と、
NMR分光光学的シグナル強度値の少なくとも1つの動的データセットを経時的に作成するため、上記脳組織化学シフト周波数において上記被験体における上記偏極ガスのNMR分光光学的シグナルを経時的に獲得する手段と、
上記動的データを評価する手段と、
上記獲得する手段及び評価する手段によって得られたデータに基づいて、上記血液脳関門を評価する手段と
を含むシステム。 - 前記評価する手段が、前記偏極ガスの前記偏極ガス通過挙動を評価し、上記ガス通過時間が、上記偏極ガスが前記膜を横切って移動して、次いで前記破壊手段の後に前記脳組織に入るのに要する時間に対応する、請求項25に記載のシステム。
- 前記脳組織が灰白質であり、前記評価手段が、血液脳関門の厚みを決定する手段を含む請求項26に記載のシステム。
- 前記評価する手段が、前記獲得する手段によって得られたデータに基づいて、脳組織の灰白質及び白質における灌流及び換気された酸素量を評価する手段を含む請求項25に記載のシステム。
- 当該システムが、
コンピューター読み取り可能なプログラムコードであって、少なくとも1つの選択された化学シフト周波数で経時的に上記被験体における偏極129XeのNMR分光光学的シグナルを獲得して、NMR分光光度測定シグナル強度値の少なくとも1つの動的データセットを経時的に作成するプログラムコードと、
コンピューター読み取り可能なプログラムコードであって、(a)組織、膜、又は裏打ちのような生理学的障壁の厚みの定量、(b)管腔又はチャネルの幅の定量、(c)特定の生体系又は膜の生理学的機能の妥当性の評価、(d)生理学的な障壁、構造、管腔又はチャネルの分裂又は損なわれた完全性の特定、及び/又はそれらと関連する障害の特定、並びに(e)脳の複数の区画にまたがる上記脳に関連する多様な化学シフトでの動的データの同時取得に基づいて上記脳の脳灌流マップを提供することの、少なくとも1つのために上記動的データセットを解析するプログラムコードと
を含むコンピューター読み取り可能なプログラムコードが組み込まれたコンピューター読み取り可能な記憶媒体を含む、請求項1又は請求項25に記載のシステム。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32377501P | 2001-09-20 | 2001-09-20 | |
PCT/US2002/028430 WO2003025606A1 (en) | 2001-09-20 | 2002-09-06 | Methods for in vivo evaluation of physiological conditions and/or organ or system function including methods to evaluate cardiopulmonary disorders such as chronic heart failure using polarized 129xe |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005503221A JP2005503221A (ja) | 2005-02-03 |
JP4283675B2 true JP4283675B2 (ja) | 2009-06-24 |
Family
ID=23260667
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003529182A Expired - Fee Related JP4283675B2 (ja) | 2001-09-20 | 2002-09-06 | 偏極129xeを用いる慢性心不全のような心肺障害を評価するための方法を含む、生理学的状態、および/または器官もしくは系の機能のインビボ評価のための方法 |
Country Status (6)
Country | Link |
---|---|
US (2) | US6991777B2 (ja) |
EP (1) | EP1436637A1 (ja) |
JP (1) | JP4283675B2 (ja) |
AU (2) | AU2002332896B2 (ja) |
CA (1) | CA2458901A1 (ja) |
WO (1) | WO2003025606A1 (ja) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60139457D1 (de) * | 2000-02-02 | 2009-09-17 | Gen Hospital Corp | Ungen unter verwendung einer geweberisikokarte |
US6915151B2 (en) * | 2001-02-08 | 2005-07-05 | Trustees Of The University Of Pennsylvania | Quantitative pulmonary imaging |
US20050130321A1 (en) * | 2001-04-23 | 2005-06-16 | Nicholson Jeremy K. | Methods for analysis of spectral data and their applications |
CA2458901A1 (en) * | 2001-09-20 | 2003-03-27 | Medi-Physics, Inc. | Methods for in vivo evaluation of physiological conditions and/or organ or system function including methods to evaluate cardiopulmonary disorders such as chronic heart failure using polarized 129xe |
US7179450B2 (en) * | 2001-09-20 | 2007-02-20 | Medi-Physics, Inc. | Methods for in vivo evaluation of pulmonary physiology and/or function using NMR signals of polarized Xe |
FR2848750B1 (fr) * | 2002-12-13 | 2007-02-09 | Centre Nat Rech Scient | Procede d'acquisition de signaux electromagnetiques et produit de contraste pour une telle acquisition |
US20070093697A1 (en) * | 2005-10-21 | 2007-04-26 | Theranova, Llc | Method and apparatus for detection of right to left shunting in the cardiopulmonary vasculature |
US7411396B1 (en) * | 2006-05-08 | 2008-08-12 | General Electric Company | Method and system of magnetic resonance spectroscopy with volume element dissection |
CA3065182C (en) | 2006-10-03 | 2022-05-17 | Duke University | Systems and methods for assessing pulmonary gas transfer using hyperpolarized 129xe mri |
CA2687106A1 (en) * | 2007-05-16 | 2008-11-20 | Yeda Research And Development Co. Ltd. | Assessment of blood-brain barrier disruption |
WO2013057697A1 (en) | 2011-10-19 | 2013-04-25 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Magnetic resonance maps for analyzing tissue |
GB201202964D0 (en) * | 2012-02-21 | 2012-04-04 | Binding Site Group The Ltd | Correction method |
US9396528B2 (en) * | 2013-03-15 | 2016-07-19 | Digitalglobe, Inc. | Atmospheric compensation in satellite imagery |
EP2988668B1 (en) | 2013-04-24 | 2019-07-24 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Magnetic resonance maps for analyzing tissue |
WO2017053799A1 (en) * | 2015-09-25 | 2017-03-30 | Oregon Health & Science University | Systems and methods for functional imaging of the placenta |
KR101774888B1 (ko) | 2016-10-31 | 2017-09-06 | 가천대학교 산학협력단 | 자기공명분광신호 전처리 장치 및 자기공명분광신호 전처리 방법 |
US10677874B2 (en) * | 2018-02-20 | 2020-06-09 | Wisconsin Alumni Research Foundation | System and method for control of hyperpolarized gas-phase contamination in spectroscopic magnetic resonance imaging |
US11944424B2 (en) | 2018-05-18 | 2024-04-02 | Duke University | Dynamic 129Xe gas exchange spectroscopy |
CN114236443B (zh) * | 2021-12-03 | 2023-07-18 | 中国科学院精密测量科学与技术创新研究院 | 用于肺部动态通气功能快速定量评估的气体mri方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5494655A (en) | 1990-03-09 | 1996-02-27 | The Regents Of The University Of California | Methods for detecting blood perfusion variations by magnetic resonance imaging |
US5190744A (en) | 1990-03-09 | 1993-03-02 | Salutar | Methods for detecting blood perfusion variations by magnetic resonance imaging |
US5522390A (en) | 1991-11-21 | 1996-06-04 | U.S. Philips Corporation | Magnetic resonance imaging method |
US5352979A (en) | 1992-08-07 | 1994-10-04 | Conturo Thomas E | Magnetic resonance imaging with contrast enhanced phase angle reconstruction |
US5545396A (en) | 1994-04-08 | 1996-08-13 | The Research Foundation Of State University Of New York | Magnetic resonance imaging using hyperpolarized noble gases |
US5509412A (en) | 1994-08-24 | 1996-04-23 | Wisconsin Alumni Research Foundation | Magnetic resonance imaging of blood volume |
EP1066537A1 (en) * | 1998-03-18 | 2001-01-10 | Magnetic Imaging Technologies Inc. | MR METHODS FOR IMAGING PULMONARY AND CARDIAC VASCULATURE AND EVALUATING BLOOD FLOW USING DISSOLVED POLARIZED ?129 Xe |
JP2003526437A (ja) * | 2000-03-13 | 2003-09-09 | メディ−フィジックス・インコーポレイテッド | ガス状過分極129Xeの直接注射を使用する診断処置並びに関連するシステムおよび生成物 |
CA2458901A1 (en) * | 2001-09-20 | 2003-03-27 | Medi-Physics, Inc. | Methods for in vivo evaluation of physiological conditions and/or organ or system function including methods to evaluate cardiopulmonary disorders such as chronic heart failure using polarized 129xe |
-
2002
- 2002-09-06 CA CA002458901A patent/CA2458901A1/en not_active Abandoned
- 2002-09-06 JP JP2003529182A patent/JP4283675B2/ja not_active Expired - Fee Related
- 2002-09-06 WO PCT/US2002/028430 patent/WO2003025606A1/en active Application Filing
- 2002-09-06 AU AU2002332896A patent/AU2002332896B2/en not_active Ceased
- 2002-09-06 EP EP02798934A patent/EP1436637A1/en not_active Withdrawn
- 2002-09-06 US US10/236,156 patent/US6991777B2/en not_active Expired - Fee Related
-
2005
- 2005-09-12 US US11/224,204 patent/US20060002856A1/en not_active Abandoned
-
2009
- 2009-05-08 AU AU2009201836A patent/AU2009201836A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1436637A1 (en) | 2004-07-14 |
US20030064023A1 (en) | 2003-04-03 |
AU2002332896B2 (en) | 2009-05-28 |
JP2005503221A (ja) | 2005-02-03 |
WO2003025606A1 (en) | 2003-03-27 |
CA2458901A1 (en) | 2003-03-27 |
US20060002856A1 (en) | 2006-01-05 |
AU2009201836A1 (en) | 2009-06-04 |
US6991777B2 (en) | 2006-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4283675B2 (ja) | 偏極129xeを用いる慢性心不全のような心肺障害を評価するための方法を含む、生理学的状態、および/または器官もしくは系の機能のインビボ評価のための方法 | |
US7867477B2 (en) | Methods for in vivo evaluation of pulmonary physiology and/or function using NMR signals of polarized 129Xe | |
CA2324269C (en) | Mr methods for imaging pulmonary and cardiac vasculature and evaluating blood flow using dissolved polarized 129xe | |
US7357917B2 (en) | Diagnostic procedures using 129Xe spectroscopy characterstic chemical shift to detect pathology in vivo | |
JP2009106788A (ja) | 呼吸器の障害又は慢性心不全のような心肺の障害のインビボ評価のための偏極129Xe造影剤 | |
AU2002332896A1 (en) | Methods for in vivo evaluation of physiological conditions and/or organ or system function including methods to evaluate cardiopulmonary disorders such as chronic heart failure using polarized 129 Xe | |
JP2003529420A (ja) | 肺の磁気共鳴イメージング法 | |
AU2002329991A1 (en) | Methods for in vivo evaluation of a physiological structure or function using polarized 129Xe | |
CN101862190A (zh) | 利用极化129Xe的NMR信号进行肺部生理机能和/或功能的体内评估的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050906 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080924 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081222 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090217 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090319 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120327 Year of fee payment: 3 |
|
LAPS | Cancellation because of no payment of annual fees |